

**Date: 13.02.2018**

Head-Listing & Compliance  
**BSE Limited**  
Phiroze Jeejeebhoy Towers  
Dalal Street, Fort  
Mumbai - 400001

**Scrip Code: 531207**

**Sub: Outcome of Board Meeting pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

Dear Sir/Madam,

This is to inform you that Board of Directors of the Company in their meeting held today, i.e. Tuesday, 13<sup>th</sup> February, 2018 (commenced at 12:30 P.M. and concluded at 01:30 P.M.), have considered and approve, inter-alia, the following business(s):

1. Consideration and Approval of the Unaudited Standalone Financial Results as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the quarter ended 31<sup>st</sup> December, 2017. **(Copy Enclosed)**
2. The Board considered and took on record, the Limited Review Report on Financial Results for the Quarter ended 31<sup>st</sup> December, 2017 as placed by the Statutory Auditor of the Company. **(Copy Enclosed)**
3. The Board took note of Statement of Investor Complaints/Grievances given Under Regulation 13(3) of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015 for the quarter ended 31<sup>st</sup> December, 2017.
4. The Board considered and approved the change of Registered Office of the Company from 703 Aster 7, Supertech Emerald Court Sector 93A, Noida, Uttar Pradesh 201304 to 103 Emperor 1, Supertech Emerald Court Sector 93A, Noida, Uttar Pradesh 201304 with effect from 13<sup>th</sup> February 2018.

Kindly take the above information on your records.

Thanking you,

Sincerely,

**For Raymed Labs Limited**

**Ajai Goyal**

**Whole Time Director**

**DIN: 02636418**

**Add: 703 Aster 7, Supertech Emerald Court  
Sector 93A, Noida – 201304 (U.P.)**

## Raymed Labs Limited

Regd. Office: 703 Aster 7, Supertech Emerald Court, Sector 93A, Noida - 201304, Uttar Pradesh, CIN: L24111UP1992PLC014240

E-Mail: raymedlabs@rediffmail.com, Website: www.raymedlab.com, Tel: 0120-2426900, 9412700300

### Annexure I to Regulation 33

#### Statement of Standalone Un-Audited Financial Results for the Quarter and Nine Months Ended on December 31, 2017

(Rs. in Lacs)

	Particulars	Quarter Ended			Nine Months Ended	
		3 Months Ended	Preceding 3 Months Ended	Corresponding 3 Months in the Previous Year Ended	Year to Date Figures for Current Year Period Ended	Year to Date Figures for Previous Year Period Ended
		31-12-2017	30-09-2017	31-12-2016	31-12-2017	31-12-2016
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited
I	<b>Revenue from Operations</b>					
	(a) Net Sales / Income from Operations (Net of excise duty)	-	-	-	-	-
	(b) Other Operating Income	-	-	-	-	-
II	<b>Other Income</b>	0.30	0.30	0.30	0.90	0.90
III	<b>Total Revenue (I+II)</b>	<b>0.30</b>	<b>0.30</b>	<b>0.30</b>	<b>0.90</b>	<b>0.90</b>
IV	<b>Expenses</b>					
	(a) Cost of materials consumed	-	-	-	-	-
	(b) Purchase of stock-in-trade	-	-	-	-	-
	(c) Changes in inventories of finished goods, in-progress and stock-in-trade	-	-	-	-	-
	(d) Employee Benefits Expenses	0.23	0.38	0.19	0.84	1.00
	(e) Finance Costs	-	-	-	-	-
	(f) Depreciation and amortisation expense	0.17	0.17	0.22	0.51	0.66
	(g) Other expenses	0.20	0.85	0.62	1.46	1.60
	<b>Total Expenses</b>	<b>0.60</b>	<b>1.40</b>	<b>1.02</b>	<b>2.81</b>	<b>3.25</b>
V	<b>Profit/(Loss) before exceptional and extraordinary items and tax (III-IV)</b>	<b>(0.30)</b>	<b>(1.10)</b>	<b>(0.72)</b>	<b>(1.91)</b>	<b>(2.35)</b>
VI	Exceptional Items	-	-	-	2.88	2.29
VII	<b>Profit/(Loss) before extraordinary items and tax (V-VI)</b>	<b>(0.30)</b>	<b>(1.10)</b>	<b>(0.72)</b>	<b>(4.79)</b>	<b>(4.64)</b>
VIII	Extraordinary items	-	-	-	-	-
IX	<b>Profit/(Loss) before tax (VII-VIII)</b>	<b>(0.30)</b>	<b>(1.10)</b>	<b>(0.72)</b>	<b>(4.79)</b>	<b>(4.64)</b>
X	<b>Tax Expense</b>					
	(1) Current tax	-	-	-	-	-
	(2) Deferred tax	-	-	-	-	-
XI	<b>Net Profit/(Loss) for the period from continuing operations (IX-X)</b>	<b>(0.30)</b>	<b>(1.10)</b>	<b>(0.72)</b>	<b>(4.79)</b>	<b>(4.64)</b>
XII	Profit/(Loss) from discontinuing operations before tax	-	-	-	-	-
XIII	Tax expense of discontinuing operations	-	-	-	-	-
XIV	<b>Profit/(Loss) from Discontinuing operations (after tax) (XII-XIII)</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
XV	<b>Profit/(Loss) for the period (XI+XIV)</b>	<b>(0.30)</b>	<b>(1.10)</b>	<b>(0.72)</b>	<b>(4.79)</b>	<b>(4.64)</b>
XVI	<b>Other Comprehensive Income</b>					
	(A) (i) Items that will not be reclassified to profit or loss	-	-	-	-	-
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-
	(B) (i) Items that will be classified to profit or loss					
	(ii) Income tax relating to items that will be reclassified to profit or loss					
XVII	<b>Total Comprehensive Income for the period (XV+XVI)</b> <b>(Comprising Profit (Loss) and Other Comprehensive Income for the Period)</b>	<b>(0.30)</b>	<b>(1.10)</b>	<b>(0.72)</b>	<b>(4.79)</b>	<b>(4.64)</b>
XIX	<b>Earning Per Equity Share</b>					
	(a) Basic	-0.007	-0.026	-0.017	0.112	-0.109
	(b) Diluted	-0.007	-0.026	-0.017	0.112	-0.109

**Notes:**

- (1) The above results have been reviewed by Audit Committee and taken on record by the Board of Directors at its Meeting held on 13th day of February 2018. The Statutory Auditors have carried out a Limited Review of the above results.
- (2) The above results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (IND AS), prescribed under section 133 of the Companies Act, 2013 and other recognized accounting practices and policies to the extent applicable.
- (3) The statement does not include Ind AS compliant results for previous year ended March 31, 2017 as the same is not mandatory as per SEBI circular dated July 5, 2016.
- (4) The IND AS compliant corresponding figures for the quarter and nine months ended 31st December, 2016 have not been subjected to limited review or audit. However, the Company's management has exercised necessary due diligence to ensure that such financial results provide a true and fair view of its affairs.
- (5) The figures for the previous period have been regrouped/reclassified, wherever necessary, to make them comparable.
- (6) As the Company's business activity falls within a single segment, therefore disclosure requirements of the Accounting Standard (AS) 17 "Segment Reporting" prescribed by Companies (Accounting Standards) Rules 2006 are not applicable.

(7) Reconciliation of Net Profit / (Loss) as previously reported under GAAP and IND AS for the period as reported above has been given in the table below:

Particulars	(Rs. In Lakhs)	
	Quarter ended 31.12.2016 (Unaudited)	Nine Months ended 31.12.2016 (Unaudited)
<b>Reconciliation of Net Profit / (Loss) as previously reported in GAAP and IND</b>		
Profit/Loss after tax as per Previous GAAP	(0.72)	(4.64)
Profit/Loss after tax as reported under Ind AS	(0.72)	(4.64)
Other Comprehensive Income	0.00	0.00
Total Comprehensive Income / (loss) as reported under Ind AS	(0.72)	(4.64)

**For Raymed Labs Limited**

Ajai Goyal  
Whole Time Director  
DIN: 02636418  
Add: 703, Aster 7, Supertech Emerald Court  
Sector 93A, Noida – 201304 (U.P)

Date: 13.02.2018  
Place: Noida



# A. Kay. Mehra & Co.

## CHARTERED ACCOUNTANTS

114 (Basement), Mall Road, Kingsway Camp, Delhi-110009  
Tel No. : 011-42461274, 9891295255, 9818708294  
E-mail : akmca1969@gmail.com Website : www.akmca.in

### INDEPENDENT AUDITOR'S LIMITED REVIEW REPORT FOR QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2017

To  
The Board of Directors  
**Raymed Labs Limited**  
703, Aster 7, Supertech Emerald Court,  
Sector 93A, Noida- 201304

1. We have reviewed the accompanying statement of unaudited financial results ("The Statement") of **Raymed Labs Limited** ("The Company") for the quarter and nine months period ended on December 31, 2017, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016.

Attention is drawn to the fact that the amounts for the corresponding quarter and nine months period ended December 31, 2016, including the reconciliation of net profit or loss under Ind AS of the said quarter and nine months period with net profit or loss reported under previous GAAP, as included in the Statement have not been subject to limited review or audit. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

2. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
3. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement prepared in accordance with applicable accounting standards, as notified under the Companies (Indian Accounting Standards) Rules, 2015 as specified in Section 133 of the Companies Act, 2013 read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016 and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: New Delhi  
Date: February 13, 2018

For A Kay Mehra & Co.  
Chartered Accountants  
(F.R.N. 050004C)  
  
CA Deepak Suneja  
Partner  
(Membership No. 501957)